» Articles » PMID: 6693639

Patterns of Creatine Kinase Release During Acute Myocardial Infarction After Nonsurgical Reperfusion: Comparison with Conventional Treatment and Correlation with Infarct Size

Overview
Date 1984 Mar 1
PMID 6693639
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Coronary arteriography and biplane ventriculography were performed in 51 patients during the acute (mean of 6.6 hours after onset of symptoms) and chronic (1 to 3 months after admission) phase of myocardial infarction. Twenty-four patients were treated in a conventional manner. In 27 patients, reperfusion was achieved with intracoronary streptokinase after 24 +/- 20 minutes of infusion. Peak creatine kinase and cumulative creatine kinase release were derived from serial creatine kinase measurements. Ejection fraction and the length of the akinetic or dyskinetic segments were calculated in the chronic phase. The time interval between onset of symptoms and peak creatine kinase was significantly shorter for the streptokinase-treated patients as compared with the conventionally treated patients (13.5 +/- 5.3 versus 22.9 +/- 7.4 hours, p = 0.0001). Significant linear correlations were obtained for both streptokinase-treated and control patients, relating: 1) peak creatine kinase value to both length of the noncontracting segment and ejection fraction in the chronic phase, and 2) cumulative creatine kinase release to both length of the noncontracting segment and ejection fraction in the chronic phase. Patients treated with streptokinase experienced a relatively greater release of enzyme for a given infarct size as compared with those treated in a conventional manner. The difference in enzyme release between the two groups increased as infarct size increased. These observations may be explained by enhanced washout of enzyme from the infarct zone, secondary to reperfusion after intracoronary streptokinase therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction.

Turer A, Mahaffey K, Gallup D, Weaver W, Christenson R, Every N Curr Control Trials Cardiovasc Med. 2005; 6:12.

PMID: 16115321 PMC: 1236947. DOI: 10.1186/1468-6708-6-12.


Ten year mortality in relation to original size of myocardial infarct: results from the Gothenburg metoprolol study.

Herlitz J, Karlson B, Hjalmarson A Br Heart J. 1994; 71(3):238-41.

PMID: 8142192 PMC: 483660. DOI: 10.1136/hrt.71.3.238.


Prediction of spontaneous coronary reperfusion in myocardial infarction.

Verheugt F, Visser F, van der Wall E, van Eenige M, Res J, ROOS J Postgrad Med J. 1986; 62(733):1007-10.

PMID: 3306639 PMC: 2418960. DOI: 10.1136/pgmj.62.733.1007.


Effect of nifedipine on enzymatically estimated infarct size in the early phase of acute myocardial infarction.

Walker L, MacKenzie G, Adgey A Br Heart J. 1988; 59(4):403-10.

PMID: 3285877 PMC: 1216484. DOI: 10.1136/hrt.59.4.403.


A randomised dose ranging study of recombinant tissue plasminogen activator in acute myocardial infarction.

McNeill A, Shannon J, Cunningham S, Flannery D, Campbell N, Khan M Br Med J (Clin Res Ed). 1988; 296(6639):1768-71.

PMID: 3136831 PMC: 2546238. DOI: 10.1136/bmj.296.6639.1768.